Vertaling van "ratings of novartis during " (Nederlands → Frans) :

Credit agencies maintained their ratings of Novartis during the first half of 2010.
Au deuxième trimestre 2010, les agences de notation ont maintenu leurs notes pour Novartis.

Credit agencies maintained their ratings of Novartis debt during the first quarter of 2010.
Au premier trimestre 2010, les agences de notation ont maintenu leurs notes pour la dette de Novartis.

Credit agencies have maintained their ratings of Novartis debt during 2009.
En 2009, les agences de notation ont maintenu leurs notes pour la dette de Novartis.

Credit agencies maintained their ratings of Novartis debt during 2009.
En 2009, les agences de notation ont maintenu leurs notes pour la dette de Novartis.

Credit agencies maintained their ratings of Novartis debt during the first half of 2009.
Au premier semestre 2009, les agences de notation ont maintenu leurs notes pour la dette de Novartis.

Distinct energy programmation during brady-pacing and post shock Programmable minimal and maximal heart rate Activity sensor and rate response Rate Hysteresis ProgrammableAV delay after atrial sense or pace Anti-PMT algorithm Defibrillation Defibrillation or ATP VT/SVT discrimination algorithms Event Counters Heart Rate time interval diagnostics Stored intracardiac electrograms Distinct programmation of right/left ventricular stimulation 4 years warranty on longevity 3 years warranty on longevity
Distinct energy programmation during brady-pacing and post shock Programmable minimal and maximal heart rate Activity sensor and rate response Rate Hysteresis Programmable AV delay after atrial sense or pace Anti-PMT algorithm Defibrillation Defibrillation or ATP VT/SVT discrimination algorithms Event Counters Heart Rate time interval diagnostics Stored intracardiac electrograms Distinct programmation of right/left ventricular stimulation 4 years warranty on longevity 3 years warranty on longevity

Based on the Novartis closing share price of CHF 56.50 on December 30, 2009 (the last trading day on the SIX Swiss Stock Exchange before the announcement) and an exchange rate of CHF 1.04 = USD 1.00, this proposal represents an implied price of USD 153 per Alcon share and a 12% premium to Alcon’s unaffected publicly traded share price as determined by Novartis of USD 137 per share.
Sur la base du cours de clôture de l’action Novartis s’élevant à CHF 56,50 au 30 décembre 2009 (le dernier jour de négoce au SIX Swiss Stock Exchange avant l’annonce) et d’un taux de change de CHF 1,04 pour USD 1,00, cette proposition représente un prix implicite d’USD 153 par action Alcon et une prime de 12% sur le cours non affecté d’USD 137 de l’action Alcon négociée en Bourse.

Gender discrimination litigation In November 2004, certain female pharmaceutical sales representatives brought a class action lawsuit in the SDNY against NPC, Novartis Corporation and a Novartis executive alleging claims of past gender discrimination during the period of 2002 to 2007.
Litige portant sur la discrimination sexuelle En novembre 2004, certaines déléguées médicales ont déposé auprès du SDNY une plainte collective contre NPC, Novartis Corporation et un directeur de Novartis pour discrimination sexuelles entre 2002 et 2007.